financetom
Business
financetom
/
Business
/
Swiss Water Renewed and Expanded its Credit Facilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Swiss Water Renewed and Expanded its Credit Facilities
Jun 25, 2025 4:37 AM

07:17 AM EDT, 06/25/2025 (MT Newswires) -- Swiss Water Decaffeinated Coffee ( SWSSF ) , a specialty coffee company and premium green coffee decaffeinator, overnight Tuesday said it completed the renewal and amendment of its existing revolving credit facility resulting in an $80 million revolving credit facility.

A company statement noted that the amended revolving facility provides it with $35 million of incremental borrowing capacity, consisting of $10 million of expanded revolving credit capacity with CIBC and the introduction of $25 million of incremental revolving credit capacity with Rabobank.

The amended revolving facility, with a maturity date of June 23, 2027, replaces the company's current credit facilities with CIBC, which matures on October 19. The new agreement includes an option to extend maturity by one year, to June 23, 2028.

The company stated that the increased revolving credit capacity is being made available for working capital, "particularly in light of increased sales volumes and elevated coffee prices."

"Not only does this important milestone enhance our ability to service our customers within the context of an extremely volatile coffee market, but it is a statement of support for our Company, and confidence in our team's ability to accelerate the growth of our business as the market continues to embrace our chemical-free decaffeinated coffee," said Swiss Water Decaffeinated Coffee's ( SWSSF ) Chief Financial Officer, Iain Carswell.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Jul 11, 2024
On Thursday, Pfizer Inc. ( PFE ) announced that, based on results from the ongoing Phase 1 pharmacokinetic study, it has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer ( PFE ) plans to conduct dose optimization studies in the second half of 2024, evaluating multiple doses of the preferred modified...
SentinelOne, Aon Collaborate to Mitigate Cyber Risk
SentinelOne, Aon Collaborate to Mitigate Cyber Risk
Jul 11, 2024
09:44 AM EDT, 07/11/2024 (MT Newswires) -- SentinelOne ( S ) and Aon (AON) are partnering to gather internal security data from SentinelOne ( S ) clients to more effectively manage and mitigate cyber risk, the companies said Thursday. SentinelOne ( S ) will provide threat detection and response technology through its Singularity Platform while Aon will assist clients using...
Cornish Metals Starts Second Phase of Shaft Refurbishment at South Crofty Tin Project in U.K.
Cornish Metals Starts Second Phase of Shaft Refurbishment at South Crofty Tin Project in U.K.
Jul 11, 2024
09:42 AM EDT, 07/11/2024 (MT Newswires) -- Cornish Metals ( SBWFF ) , trading at 52 week lows, on Thursday said it has begun the second phase of shaft refurbishment at its South Crofty tin project in Cornwall, England. Vancouver-based Cornish also said it had received the initial payment for the sale of the Nickel King asset in the Northwest...
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar
Jul 11, 2024
09:45 AM EDT, 07/11/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Thursday that 12-month data from a mid-stage clinical trial showed the longevity of effect of eRapa in the treatment of precancerous polyps in the gastrointestinal tract. The company said that based on the data, eRapa showed an overall 17% median decrease in overall polyp burden and non-progression...
Copyright 2023-2026 - www.financetom.com All Rights Reserved